Vrati se na sadržaj

Onkologija

Lečenje anemije

Lekovi za stimulaciju eritropoeze

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (otvara novi prozor)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Izvor‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indeks‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (otvara novi prozor)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (otvara novi prozor)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Izvor‎: Acta Haematol 2007;117(3):162-7.

Indeks‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (otvara novi prozor)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (otvara novi prozor)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Izvor‎: Am J Hematol 2013;88(12):990-6.

Indeks‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (otvara novi prozor)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (otvara novi prozor)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Izvor‎: J Clin Oncol 2011;29(28):3791-7.

Indeks‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (otvara novi prozor)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (otvara novi prozor)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Izvor‎: Cancer 2012;118(3):848-55.

Indeks‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (otvara novi prozor)

Management of anemia in cancer patients. (otvara novi prozor)

Calabrich A, Katz A.

Izvor‎: Future Oncol 2011;7(4):507-17.

Indeks‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (otvara novi prozor)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (otvara novi prozor)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Izvor‎: BJU Int 2011;108(10):1582-7.

Indeks‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (otvara novi prozor)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (otvara novi prozor)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Izvor‎: J Clin Oncol 2010;28(13):2239-45.

Indeks‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (otvara novi prozor)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (otvara novi prozor)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Izvor‎: Br J Cancer 2011;105(9):1267-72.

Indeks‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (otvara novi prozor)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (otvara novi prozor)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Izvor‎: J Intern Med 2017;281(3):284-99.

Indeks‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (otvara novi prozor)

How I treat cancer-associated anemia. (otvara novi prozor)

Gilreath JA, Rodgers GM

Izvor‎: Blood 2020;136(7):801-13.

Indeks‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (otvara novi prozor)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (otvara novi prozor)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Izvor‎: Eur J Haematol. 2023 110(4):354-61.

Indeks‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (otvara novi prozor)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (otvara novi prozor)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Izvor‎: Int J Hematol 2015;102(4):401-12.

Indeks‎: PubMed 26323997

DOI‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (otvara novi prozor)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (otvara novi prozor)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Izvor‎: Cancer 2013;119(1):107-14.

Indeks‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (otvara novi prozor)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (otvara novi prozor)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Izvor‎: J Natl Cancer Inst 2013;105(14):1018-26.

Indeks‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (otvara novi prozor)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (otvara novi prozor)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Izvor‎: Cancer Sci 2013;104(4):481-5.

Indeks‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (otvara novi prozor)

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (otvara novi prozor)

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

Izvor‎: Br J Haematol 2019;184(2):134-60.

Indeks‎: PubMed 30549002

DOI‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 (otvara novi prozor)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (otvara novi prozor)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Izvor‎: Support Care Cancer 2012;20(1):159-65.

Indeks‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (otvara novi prozor)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (otvara novi prozor)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Izvor‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indeks‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (otvara novi prozor)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (otvara novi prozor)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Izvor‎: Oncologist 2010;15(9):935-43.

Indeks‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (otvara novi prozor)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (otvara novi prozor)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Izvor‎: Lung Cancer 2012;76(3):478-85.

Indeks‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (otvara novi prozor)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (otvara novi prozor)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Izvor‎: Eur J Haematol 2016;97(1):33-8.

Indeks‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (otvara novi prozor)

Preparati govožđa za intravensku primenu

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (otvara novi prozor)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Izvor‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indeks‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (otvara novi prozor)

Intravenous iron in oncology. (otvara novi prozor)

Auerbach M, Ballard H.

Izvor‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Indeks‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (otvara novi prozor)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (otvara novi prozor)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Izvor‎: Int J Colorectal Dis 2016;31(3):543-51.

Indeks‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (otvara novi prozor)

How I treat cancer-associated anemia. (otvara novi prozor)

Gilreath JA, Rodgers GM

Izvor‎: Blood 2020;136(7):801-13.

Indeks‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (otvara novi prozor)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (otvara novi prozor)

Gilreath JA, Stenehjem DD, Rodgers GM.

Izvor‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Indeks‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (otvara novi prozor)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (otvara novi prozor)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Izvor‎: Eur J Haematol. 2023 110(4):354-61.

Indeks‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (otvara novi prozor)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (otvara novi prozor)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Izvor‎: Curr Oncol. 2023 24;30(9):7836-51.

Indeks‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (otvara novi prozor)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (otvara novi prozor)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Izvor‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Indeks‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (otvara novi prozor)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (otvara novi prozor)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Izvor‎: World J Gastroenterol 2014;20(8):1972-85.

Indeks‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (otvara novi prozor)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (otvara novi prozor)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Izvor‎: South Asian J Cancer. 2023 15;12(2):93-9.

Indeks‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (otvara novi prozor)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (otvara novi prozor)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Izvor‎: J Clin Oncol 2008;26(10):1619-25.

Indeks‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (otvara novi prozor)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (otvara novi prozor)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Izvor‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Indeks‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (otvara novi prozor)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (otvara novi prozor)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Izvor‎: Ann Oncol 2013;24(2):475-82.

Indeks‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (otvara novi prozor)

ONKOLOGIJA
Lečenje anemije
srpski (latinica)
Lečenje anemije
https://assetsnffrgf-a.akamaihd.net/assets/ct/5a91b826b0/images/syn_placeholder_sqr.png

Kontakt s lokalnim predstavnicima

Međunarodna služba dostupna 24 sata besplatno sarađuje s lekarima specijalistima koji leče Jehovine svedoke.

Kontakt

Medicinske informacije

Ovde se možete informisati o kliničkim strategijama za zaustavljanje krvarenja i lečenje anemije bez transfuzije krvi, verskom i etičkom stavu Jehovinih svedoka o medicinskom lečenju i uslugama koje Svedoci pružaju lekarskim društvima preko svoje međunarodne mreže Odbora za odnose s bolnicama.

Pogledaj sadržaje

Filmovi

Filmovi o metodama lečenja bez krvi, kao i o čestim medicinskim i etičkim pitanjima, namenjeni lekarima koji leče Jehovine svedoke.

Pogledaj filmove